The recent breakthroughs in the understanding of host genomics in hepatitis C

European Journal of Clinical Investigation

Volumn 40, Issue 10, 2010, Pages 950-959

  Rauch, Andri ^a   Rohrbach, Janine ^a   Bochud, Pierre Yves ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Hepatitis C treatment; hepatitis C virus; host genomics; interleukin 28B; spontaneous clearance

Indexed keywords

CYTOKINE; INTERLEUKIN 28; INTERLEUKIN 28B; JANUS KINASE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; STAT PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CHROMOSOME 19; GENE; GENE EXPRESSION REGULATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOMICS; HEPATITIS C; HEREDITY; HOST; HUMAN; IL28B GENE; INFECTION CONTROL; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERLEUKINS; LIPOPROTEINS, LDL; MALE; REMISSION, SPONTANEOUS; RNA;

EID: 77956547987     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02337.x     Document Type: Review

References (30)

1. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999 340 : 1228 1233.
2. Muller R. The natural history of hepatitis C: clinical experiences. J Hepatol 1996 24 : 52 4.
3. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000 284 : 450 456.
4. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006 13 : 34 41.
5. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008 49 : 634 651.
6. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004 350 : 2265 2271.
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965. (Pubitemid 32913521)
8. Rauch A, Gaudieri S, Thio C, Bochud PY. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 2009 10 : 1819 1837.
9. Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis 2008 12 : 713 726.
10. Asselah T, Bieche I, Paradis V, Bedossa P, Vidaud M, Marcellin P. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 2007 27 : 13 27.
11. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von EE et al. STrengthening the REporting of Genetic Association studies (STREGA) - an extension of the STROBE statement. Eur J Clin Invest 2009 39 : 247 266.
12. Telenti A, Goldstein DB. Genomics meets HIV-1. Nat Rev Microbiol 2006 4 : 865 873.
13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009 461 : 399 401.
14. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009 41 : 1105 1109.
15. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009 41 : 1100 1104.
16. Rauch A, Kutalik Z, Descombes P, Cai T, Di IJ, Mueller T et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010 138 : 1338 1345.
17. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010 138 : 2307 2314.
18. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'huigin C et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009 461 : 798 801.
19. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010 51 : 1904 1911.
20. Shinohara E, Yamashita S, Kihara S, Hirano K, Ishigami M, Arai T et al. Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology 1997 25 : 1502 1506.
21. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008 105 : 7034 7039.
22. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003 4 : 63 8.
23. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003 4 : 69 77.
24. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008 4 : e1000017.
25. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009 86 : 23 32.
26. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006 131 : 1887 1898.
27. Dodds MG, Hausman DF, Miller DM. Viral Kinetic Modeling During Treatment with Interferon Lamda-1a in Genotype 1 Chronic Hepatitis C Patients. European Association for the Study of the Liver (EASL), 44th Annual Meeting, Copenhagen, Denmark (Abstr 2009.
28. Lawitz E, Zaman A, Muir AJ. Interim results from a phase 1b dose-escalation study of 4 weeks of PEG-interferon lambda (PEG-rIL-29) treatment in subjects with hepatitis C virus (HCV) genotype 1 with prior virologic response and relapse to peginterferon alfa and ribavirin. Hepatology. 2008 48 : A-170 (Abstr).
29. Miller DM, Klucher KM, Freeman JA, Hausman DF, Fontana D, Williams DE. Interferon lambda as a potential new therapeutic for hepatitis C. Ann N Y Acad Sci 2009 1182 : 80 7.
30. Mosbruger TL, Duggal P, Goedert JJ, Kirk GD, Hoots WK, Tobler LH et al. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis 2010 201 : 1371 1380.